Table 1. Patient characteristics.

patient ID	age	gender	cTNM	cStage	neoadjuvant treatment	surgical resection	hist	pTNM	pstage	ctc	recurrence	death
6	66	m	cT1bN0	I	N	Y	G3	pT1bN2	IIIA	3	Y	Y
25	62	m	cT2N0	IIB	N	Y	G3	pT3N2	IIIB	3	N	N
28	49	m	cT2N0	IIB	N	Y	G3	pT3N1	IIIB	1	Y	N
1	60	m	cT1bN0	I	N	Y	G2	pT1aN0	IB	1	N	N
15	80	v	cT3N0	III	N	Y	G3	pT4aN0	IIIB	6	Y	Y
13	69	v	cT3N1	III	CROSS	Y	GX	ypT0N2	IIIB	1	Y	Y
23	64	v	cT4aN1	III	FLOT	Y	/	/	/	1	Y	Y
32G	55	m	ypT2N1M+	IVB	CROSS	Y	G2	ypT2N1M1	IIIA	5	/	Y
30	70	m	cT1bN0	I	N	Y	G1	pT1bN0	IB	0	N	N
21	62	m	cT1bN0	I	N	Y	G2	pT1bN0	IB	0	N	N
22	63	m	cT1bN0	I	N	Y	G2	pT1bN0	IB	0	Y	N
3	71	m	cT1bN0	I	N	Y	G2	pT1bN0	IB	0	Y	Y°
24	73	m	cT1bN0	I	N	Y	G3	pT1bN0	IC	0	Y	Y
26	72	m	cT2N0	IIB	N	Y	G1	pT1bN0	IB	0	N	N
29	62	m	cT2N0	IIB	N	Y	G2	pT2N0	IC	0	N	N
32	57	m	cT2N0	IIB	N	Y	G3	pT4aN2	IVA	0	Y	Y
27	83	v	cT3N0	III	N	Y	G2	pT3N0	IIB	0	N	N°
14	59	m	cT3N1	III	CROSS	Y	G1	ypT3N2	IIIB	0	Y	N
5	70	m	cT3N1	III	mCROSS	Y	G2	ypT1aN0	I	0	Y	N
10	71	m	cT3N1	III	mCROSS	Y	G2	ypT3N2	IIIB	0	Y	N
11	58	m	cT3N1	III	mCROSS	Y	G3	ypT3N2	IIIB	0	Y	Y
16	65	m	cT3N1	III	CROSS	Y	G3	ypT3N2	IIIB	0	Y	Y
17	66	m	cT3N1	III	mCROSS	Y	G3	ypT3N0	II	0	N	N
20	63	m	cT3N1	III	mCROSS	Y	/	/	/	0	Y	Y
36G	67	m	cT3N2	IVA	CROSS	Y	GX	ypT2N1	IIIA	0	Y	Y
31G	51	m	cT3N2M+	IVB	Multiple CTs	N	G2	/	/	0	/	Y
33G	51	m	ypT3N3M+	IVB	CP-5FU + RT 30Gy	Y	G3	ypT3N3M1	IVA	0	/	Y
34G	71	m	ypT3N2M+	IVB	CROSS	Y	G1	ypT3N2M1	IIIB	0	/	Y
42G	72	m	ypT3N1M+	IVB	CROSS	Y	G3	ypT3N1M1	IVB	0	/	Y

cStage: clinical stage; pStage: pathologic stage [18]; m: male; f: female; Y: yes; N: no; Hist: histologic grade definitions for EAC; G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated; G4: undifferentiated; GX: histologic differentiation could not be determined; y: status after completing nRCT; CTs: chemotherapies; ctc: number of CTCs found in peripheral blood using the Parsortix device; recurrence: status of disease recurrence after curative intent in EAC; death: status of cancer-related-survival after treatment;

° second primary tumor.